AR061506A1 - 3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer. - Google Patents
3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer.Info
- Publication number
- AR061506A1 AR061506A1 ARP070102670A ARP070102670A AR061506A1 AR 061506 A1 AR061506 A1 AR 061506A1 AR P070102670 A ARP070102670 A AR P070102670A AR P070102670 A ARP070102670 A AR P070102670A AR 061506 A1 AR061506 A1 AR 061506A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- extraction
- alkynyl
- Prior art date
Links
- 238000000605 extraction Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 238000002955 isolation Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000035658 Raspailiidae Species 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000013599 spices Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compuestos antitumorales obtenidos de una porífera, de la familia Raspailiidae, género Lithoplocamia, especia lithistoides, y derivados de los mismos, composiciones farmacéuticas que los contienen, su uso en medicamentos para el tratamiento del cáncer y métodos para su extraccion. Reivindicacion 1: Un compuesto de formula general 1 en donde R1 es seleccionado entre hidrogeno, ORa, OCORa, OCOORa, NRaRb, NRaCORb, y NRaC(NRa)NRaRb; cada R2 y R3 son independientemente seleccionados entre hidrogeno, aIquiIo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido y alquinilo C2-12 sustituido o no sustituido; cada R41, R42, R43, R44, R45, R46, R47 y R48 son independientemente seleccionados entre hidrogeno, alquilo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido y alquinilo C2-12 sustituido o no sustituido; cada R5, R6, y R7 son independientemente seleccionados entre hidrogeno, CORa, COORa, alquilo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido y alquinilo C2-12 sustituido o no sustituido, o R5 y R48 junto con el correspondiente átomo de N y C al que están unidos pueden formar un grupo heterocíclico sustituido o no sustituido; cada Ra y Rb son independientemente seleccionados entre hidrogeno, alquilo C1-12 substituido o no substituido, alquenilo C2-12 sustituido o no sustituido, alquinilo C2-12 sustituido o no sustituido, arilo sustituido o no sustituido y grupo heterocíclico sustituido o no sustituido; y cada línea de puntos representa la presencia opcional de un enlace adicional; o una sal farmacéuticamente aceptable, un derivado, un tautomero, una prodroga o un estereoisomero del mismo. Reivindicacion 22: Un procedimiento para la obtencion de un compuesto segun se define en una cualquiera de las reivindicaciones precedentes, o una sal farmacéuticamente aceptable, un derivado, un tautomero, una prodroga o un estereoisomero del mismo, que comprende las etapas de extraccion y aislamiento a partir de Lithoplocamia lithistoides.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380173 | 2006-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061506A1 true AR061506A1 (es) | 2008-09-03 |
Family
ID=38508885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102670A AR061506A1 (es) | 2006-06-16 | 2007-06-19 | 3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8324406B2 (es) |
| EP (3) | EP2404913A3 (es) |
| JP (2) | JP5117491B2 (es) |
| KR (1) | KR101474031B1 (es) |
| CN (2) | CN101679340B (es) |
| AR (1) | AR061506A1 (es) |
| AT (1) | ATE522514T1 (es) |
| AU (1) | AU2007259257B8 (es) |
| BR (2) | BRPI0713031B8 (es) |
| CA (1) | CA2654334C (es) |
| CY (1) | CY1112103T1 (es) |
| DK (1) | DK2032551T3 (es) |
| ES (1) | ES2371942T3 (es) |
| HR (1) | HRP20110845T1 (es) |
| IL (1) | IL195676A (es) |
| MX (1) | MX2008015754A (es) |
| MY (1) | MY145788A (es) |
| NO (2) | NO341508B1 (es) |
| NZ (1) | NZ573706A (es) |
| PL (1) | PL2032551T3 (es) |
| PT (1) | PT2032551E (es) |
| RS (1) | RS52034B (es) |
| RU (2) | RU2444519C2 (es) |
| SG (1) | SG174830A1 (es) |
| SI (1) | SI2032551T1 (es) |
| TW (2) | TWI373469B (es) |
| UA (1) | UA97369C2 (es) |
| WO (1) | WO2007144423A1 (es) |
| ZA (1) | ZA200810315B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140015T1 (hr) * | 2007-12-20 | 2014-02-14 | Pharma Mar, S.A. | Antitumorski spojevi |
| WO2009104147A2 (en) | 2008-02-20 | 2009-08-27 | Actelion Pharmaceuticals Ltd | Azatricyclic antibiotic compounds |
| WO2009104159A1 (en) | 2008-02-22 | 2009-08-27 | Actelion Pharmaceuticals Ltd | Oxazolidinone derivatives |
| CN104151316B (zh) | 2008-10-07 | 2016-06-15 | 埃科特莱茵药品有限公司 | 三环噁唑烷酮抗生素化合物 |
| KR101667066B1 (ko) | 2008-10-10 | 2016-10-17 | 액테리온 파마슈티칼 리미티드 | 옥사졸리디닐 항생제 |
| WO2010149688A2 (en) | 2009-06-24 | 2010-12-29 | Pharma Mar, S.A. | Antitumoral compounds |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| CN108467378A (zh) * | 2017-02-23 | 2018-08-31 | 复旦大学 | 一种二氢吡喃酮类化合物及其制备方法和用途 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| CN110790737B (zh) * | 2019-11-07 | 2022-07-22 | 河南中烟工业有限责任公司 | 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法 |
| CN118139851A (zh) | 2021-10-22 | 2024-06-04 | 法马马有限公司 | 抗肿瘤化合物 |
| CN117510448A (zh) * | 2023-11-13 | 2024-02-06 | 贵州中医药大学 | 一种二氢吡喃酮衍生物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA938019B (en) * | 1992-11-13 | 1995-04-28 | Upjohn Co | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses |
| FI962022L (fi) * | 1993-11-19 | 1996-07-12 | Parke Davis & Co | 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina |
| US7446196B2 (en) * | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
-
2007
- 2007-06-15 AT AT07765445T patent/ATE522514T1/de active
- 2007-06-15 PT PT07765445T patent/PT2032551E/pt unknown
- 2007-06-15 DK DK07765445.7T patent/DK2032551T3/da active
- 2007-06-15 WO PCT/EP2007/055959 patent/WO2007144423A1/en not_active Ceased
- 2007-06-15 HR HR20110845T patent/HRP20110845T1/hr unknown
- 2007-06-15 RU RU2009101150/04A patent/RU2444519C2/ru active
- 2007-06-15 BR BRPI0713031A patent/BRPI0713031B8/pt not_active IP Right Cessation
- 2007-06-15 SG SG2011067998A patent/SG174830A1/en unknown
- 2007-06-15 NZ NZ573706A patent/NZ573706A/en not_active IP Right Cessation
- 2007-06-15 MX MX2008015754A patent/MX2008015754A/es active IP Right Grant
- 2007-06-15 KR KR1020097000830A patent/KR101474031B1/ko not_active Expired - Fee Related
- 2007-06-15 EP EP11177479A patent/EP2404913A3/en not_active Withdrawn
- 2007-06-15 CN CN2007800222645A patent/CN101679340B/zh not_active Expired - Fee Related
- 2007-06-15 EP EP11177474A patent/EP2404912A3/en not_active Withdrawn
- 2007-06-15 JP JP2009514811A patent/JP5117491B2/ja not_active Expired - Fee Related
- 2007-06-15 EP EP07765445A patent/EP2032551B9/en active Active
- 2007-06-15 US US12/304,123 patent/US8324406B2/en not_active Expired - Fee Related
- 2007-06-15 CA CA2654334A patent/CA2654334C/en active Active
- 2007-06-15 MY MYPI20085040A patent/MY145788A/en unknown
- 2007-06-15 ES ES07765445T patent/ES2371942T3/es active Active
- 2007-06-15 RS RS20110495A patent/RS52034B/sr unknown
- 2007-06-15 BR BRPI0722429-0A patent/BRPI0722429A2/pt not_active IP Right Cessation
- 2007-06-15 SI SI200730781T patent/SI2032551T1/sl unknown
- 2007-06-15 PL PL07765445T patent/PL2032551T3/pl unknown
- 2007-06-15 AU AU2007259257A patent/AU2007259257B8/en not_active Ceased
- 2007-06-15 CN CN2011102036625A patent/CN102336730A/zh active Pending
- 2007-06-15 UA UAA200900292A patent/UA97369C2/ru unknown
- 2007-06-19 AR ARP070102670A patent/AR061506A1/es active IP Right Grant
- 2007-06-20 TW TW096122071A patent/TWI373469B/zh not_active IP Right Cessation
- 2007-06-20 TW TW100146802A patent/TW201213316A/zh unknown
-
2008
- 2008-12-02 IL IL195676A patent/IL195676A/en active IP Right Grant
- 2008-12-04 ZA ZA2008/10315A patent/ZA200810315B/en unknown
-
2009
- 2009-01-06 NO NO20090054A patent/NO341508B1/no unknown
-
2011
- 2011-06-29 US US13/171,567 patent/US8501968B2/en not_active Expired - Fee Related
- 2011-08-05 RU RU2011133128/04A patent/RU2011133128A/ru not_active Application Discontinuation
- 2011-09-14 NO NO20111248A patent/NO20111248L/no not_active Application Discontinuation
- 2011-10-05 JP JP2011220925A patent/JP2012021023A/ja active Pending
- 2011-11-30 CY CY20111101175T patent/CY1112103T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061506A1 (es) | 3-metoxi-5, 6-dihidro-2h-piran-2-onas sustituidas, composiciones farmaceuticas que las contienen, un metodo de extraccion y aislamiento de las mismas a partir de lithoplocamia lithistoides y su empleo como medicamento para el tratamiento del cancer. | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| US10954217B2 (en) | Sigma receptor binders | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
| AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
| MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| BR122013028005B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos | |
| CL2014000363A1 (es) | Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros. | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
| PE20130149A1 (es) | Derivados de la cromenona con actividad anti-tumoral | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| AR070352A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. | |
| JP2019510027A5 (es) | ||
| DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| UY31554A1 (es) | Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
| TN2015000005A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| US20200115345A1 (en) | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | |
| US20210323913A1 (en) | Sigma receptor binders | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| AR075474A1 (es) | Inhibidores de cyp17 de decahidro-1h-indenoquinolinona y decahidro-3h-ciclopentafenantridinona, composiciones farmaceuticas y metodos de tratamiento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |